Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition
June 01 2023 - 12:30PM
Crossject - Appointment of Daniel Teper to the Crossject
Supervisory Board / Building skills to support the US transition
Press releaseDijon, 1st June 2023,
6.30 p.m.
Appointment of Daniel
Teper to the Crossject Supervisory
Board Building skills to support the US transition
CROSSJECT (ISIN: FR0011716265; Ticker:
ALCJ), a specialty pharma company that is developing and will soon
be marketing a portfolio of drugs for use in emergency
situations (epilepsy, allergic shock, overdose, asthma
attack, adrenal insufficiency, etc.), has decided to submit Daniel
Teper’s appointment as a Director on its Supervisory Board for
approval at the next Annual General Meeting, to be held on 7 June
2023.
With a PhD in Pharmacy from Paris-Saclay
University and an MBA from INSEAD, Daniel Teper is a US-based
pharmaceutical industry leader and entrepreneur with a compelling
background spanning the fields of marketing, capital markets,
strategy and development. His appointment comes at a key time for
Crossject as it prepares to organise its transition as a specialty
pharma company in the United States.
Daniel Teper began his career in the pharma
industry at the headquarters of Novartis in Basel, where he quickly
acquired increasing responsibilities in sales, marketing and new
product development in the United States.
After returning to Europe, he held the positions
of Marketing and Sales Director at Glaxo Laboratories, then
Operations Director at Laboratoires Delagrange, which was
subsequently acquired by Synthelabo (now Sanofi). He then went on
to found, develop and sell Wintec Pharma, one of France’s leading
specialty pharma companies.
As a Global Partner at EuroRSCG Havas Santé, Mr
Teper advised major pharma groups on the launch of several
world-renowned drugs. He also held the position of Partner at ISO
Healthcare Consulting (Deloitte) in New York before opening and
managing the North American office of Bionest Partners (Accenture).
Mr. Teper also founded Immune Pharmaceuticals, going on to manage
it and secure its IPO on NASDAQ, and is currently CEO of Cytovia
Therapeutics.
“His training and experience will enable Daniel
Teper to enrich our company with his expertise and strategic
vision. His in-depth knowledge of the pharmaceutical industry,
particularly in the United States, his mastery of financial markets
and his experience in product development and marketing will be
invaluable assets in our transition to the American market as a
specialty pharma,” said Patrick Alexandre, Chairman of the
Management Board.
Philippe Monnot, Chairman of the Supervisory
Board, said: “This appointment will strengthen our company and help
us achieve our growth objectives, notably by contributing to the
success of ZENEO® in the United States. We extend a warm welcome to
Daniel and look forward to benefiting from his insightful
contribution and leadership.”
Contacts
CrossjectPatrick Alexandre info@crossject.com |
Investor relations AELIUMMadina
Tall +33 (0) 1 75 77 54 67 crossject@aelium.fr |
|
Press relations Buzz
& Compagnie Mélanie Voisard +33 (0)6 12 52 53
15melanie.voisard@buzzetcompagnie.com Christelle
Distinguin +33 (0)6 09 96 51
70christelle.distinguin@buzzetcompagnie.com |
About CROSSJECT • www.crossject.com
Crossject (ISIN: FR0011716265; Ticker: ALCJ;
LEI: 969500W1VTFNL2D85A65) is developing and soon to market a
portfolio of drugs for use in emergency situations (epilepsy,
overdose, allergic shock, severe migraine, asthma attack).With its
patented needle-free self-injection system, Crossject aims to
become the world leader in self-administered emergency medication.
The company has been listed on the Euronext Growth market in Paris
since 2014, and benefits from Bpifrance funding.
- Crossject_CP_Nomination_CSjuin2023_EN_VD
Crossject (EU:ALCJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Crossject (EU:ALCJ)
Historical Stock Chart
From Apr 2023 to Apr 2024